Association of 25-hydroxyvitamin D with metabolic syndrome in patients with psoriasis: A case-control study

Acta Dermato-Venereologica

Volumn 94, Issue 2, 2014, Pages 142-145

  Orgaz Molina, Jacinto ^a   Magro Checa, César ^b   Arrabal Polo, Miguel A ^c   Raya Álvarez, Enrique ^b   Naranjo, Ramón ^a   Buendía Eisman, Agustin ^c   Arias Santiago, Salvador ^a,c  

^a Baza General Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Cardiovascular risk; Metabolic syndrome; Psoriasis; Vitamin D

Indexed keywords

BLOOD PRESSURE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSORIASIS; SUNLIGHT; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84894055944     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1642     Document Type: Article

References (33)

1. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320: 980-991.
2. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009; 205: 255-260.
3. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin d level, cardiovascular disease mortality, and all causes mortality in older U.S. adults. J Am Geriatr Soc 2009; 57: 1595-1603.
4. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
5. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 11; 296: 1735-1741.
6. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, Arrabal-Polo MÁ, García-Rodriguez S, Perandrés-López R, et al. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol 2012; 22: 337-344.
7. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556-562.
8. Arias-Santiago S, Buendía-Eisman A, Aneiros-Fernández J, Girón-Prieto MS, Gutiérrez-Salmerón MT, Mellado VG, et al. Cardiovascular risk factors in patients with lichen planus. Am J Med 2011; 124: 543-548.
9. Zold E, Barta Z, Bodolay E. Vitamin D deficiency and connective tissue disease. Vitam Horm 2011; 86: 261-286.
10. Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. J Am Acad Dermatol 2012; 67: 931-938.
11. Gisondi P, Rossini M, Di Cesare A, Idolazzi L, Farina S, Beltrami G, et al. Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol 2012; 166: 505-510.
12. Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutr J 2010; 9: 65.
13. Emaus A, Degerstrøm J, Wilsgaard T, Hansen BH, DieliConwright CM, Furberg AS, et al. Does a variation in selfreported physical activity reflect variation in objectively measured physical activity, resting heart rate, and physical fitness? Results from the Tromso study. Scand J Public Health 2010; 38 (Suppl. 5): 105-118.
14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
15. Arunabh S, Pollack S, Yeh J, Aloia JF. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 2003; 88: 157-161.
16. Botella-Carretero JI, Alvarez-Blasco F, Balsa JA, Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr 2007; 26: 573-580.
17. Wood RJ. Vitamin D and adipogenesis: new molecular insights. Nutr Rev 2008; 66: 40-46.
18. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D (3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
19. Zittermann A, Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care 2008; 11: 752-757.
20. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
21. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633-1637.
22. Wong MS, Delansorne R, Man RY, Svenningsen P, Vanhoutte PM. Chronic treatment with vitamin D lowers arterial blood pressure and reduces endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2010; 299: H1226-1234.
23. Johnson JA, Grande JP, Roche PC, Kumar R. Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol 1994; 267: E356-E360.
24. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 2004; 89-90: 121-125.
25. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119: 84-90.
26. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011; 9: 85.
27. Jorde R, Figenschau Y, Hutchinson M, Emaus N, Grimnes G. High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile. Eur J Clin Nutr 2010; 64: 1457-1464.
28. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
29. Uysal, K.T, Wiesbrock SM, Marino MW. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
30. Auwerx J, Bouillon R, Kesteloot H. Relation between 25-hydroxyvitamin D3, apolipoprotein A-I, and high density lipoprotein cholesterol. Arterioscler Thromb 1992; 12: 671-674.
31. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, et al. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009; 120: 687-698.
32. Al-Daghri NM, Alkharfy KM, Al-Saleh Y Al-Attas OS, Alokail MS, Al-Othman A, et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: a 12-month prospective study. Metabolism 2012; 61: 661-666.
33. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152: 315-323.